FeesSafety
Pluang+

Burford Capital prices $300M senior secured notes to refinance 2028 debt.

Company Fundamentals
14 Sep 2026
PRNewsWire
View Source
Neutral
Burford Capital prices $300M senior secured notes to refinance 2028 debt.

Burford Capital has priced a private offering of $300 million in 8.000% senior secured notes due 2029 through its subsidiary. The proceeds will be used to redeem its 6.250% senior notes due 2028, improving its debt maturity profile. The offering is expected to close on September 17, 2026, and is targeted at qualified institutional buyers and non-US persons. This move helps Burford manage its debt more efficiently while maintaining secured financing backed by its assets.

Burford Capital's recent private offering of $300 million in senior secured notes is notable in the current financial landscape. For readers following Financials-sector US stocks, here is Pluang's market snapshot as of Sep 15, 2026 03:21 WIB: out of 74 priced stocks, 30 rose and 44 fell. Notable movers include Morgan Stanley at USD 206.94 down 3.47%, Barclays PLC at USD 25.84 down 3.24%, and Bank of New York Mellon Corp at USD 157.66 down 3.07%.

More News

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
2 hours ago
Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
2 hours ago
New Proof of Human feature links Alien ID to Solana wallets for real user verification.

New Proof of Human feature links Alien ID to Solana wallets for real user verification.

A new Proof of Human feature allows users to link an Alien ID to any Solana wallet, verifying that a real person controls the wallet. This initiative aims to enhance trust and security in blockchain transactions by confirming human identity behind wa...

Protocol Fundamentals
Neutral
4 hours ago
Perioperative apalutamide plus ADT cuts risk of prostate cancer recurrence or death by 62% versus surgery alone

Perioperative apalutamide plus ADT cuts risk of prostate cancer recurrence or death by 62% versus surgery alone

New Phase 3 PROTEUS substudy results show that adding apalutamide plus androgen deprivation therapy (ADT) before and after surgery reduces the risk of prostate cancer recurrence or death by 62% compared to surgery alone in high-risk localized or loca...

Market News
Bullish
4 hours ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App